PerkinElmer launched comprehensive solutions for detecting SARS-CoV-2 mutations

, ,

On Mar. 9, 2021, PerkinElmer announced the launch of the PerkinElmer COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal (NS) or nasopharyngeal (NP) swab specimens.

The lateral flow immunoassay test can be used to screen or to aid in diagnoses of COVID-19 in asymptomatic or symptomatic individuals. A positive or negative result can be obtained in as little as 15 minutes to facilitate immediate isolation or treatment decisions.

Tags:


Source: PerkinElmer
Credit:

Advertise in our E-history sent to 5,000 plus company decision makers twice per month for only $300 per month. Reserve your space now! E-mail: info@LifeScienceHistory.com.